RNA Vaccine-Nanoparticle Technology for Papillomavirus Warts ID: 2022-020
An innovative approach leveraging RNA vaccine-nanoparticle technology to create personalized vaccines targeting specific strains of papillomavirus.
Photo by B. BOISSONNET / BSIP
Technology Overview
This technology addresses the challenge of warts caused by various strains of papillomavirus through a personalized vaccine approach. It involves sequencing the virus DNA from a wart sample, synthesizing mRNA for the virus's El gene, incorporating this mRNA into lipid nanoparticles, and vaccinating the patient to elicit a targeted T cell response. This method aims to specifically remove warts and prevent their recurrence by overcoming the virus's ability to evade T cell activation.
Key Advantages
- High specificity in targeting the virus strain causing the wart
- Prevents wart recurrence without surgery or painful procedures
- Reduced risk of autoimmunity and excessive inflammation
- Utilizes well-established technologies validated in other contexts, such as during the COVID-19 pandemic
Problems Addressed
- Multiplicity of papillomavirus strains and their evasion of T cell activation
- Risks and discomfort associated with traditional wart removal methods
Market Applications
- Hospital and clinical settings for enhanced precision in ultrasound neuromodulation treatments
- Integration within MRI systems for real-time adjustment of acoustic fields during treatments
- Potential expansion to diagnostic applications, such as measuring the spatial extent of brain tumors
Additional Information
Technology ID: 2022-020
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report